Wed, Nov 26, 2014, 12:38 AM EST - U.S. Markets open in 8 hrs 52 mins

Recent

% | $
Quotes you view appear here for quick access.

Titan Pharmaceuticals Inc. Message Board

  • winters_1983 winters_1983 Jan 2, 2013 7:03 AM Flag

    Priority review received!!!!!

    Titan Pharmaceuticals, Inc. ( OTCBB : TTNP ) today announced that the New Drug Application (NDA) for Probuphine® has been accepted for review and granted Priority Review designation by the U.S. Food and Drug Administration (FDA). Probuphine is a novel, subdermal implant and the first long-acting product designed to deliver six months of the drug buprenorphine hydrochloride following a single treatment. Titan submitted the NDA for the maintenance treatment of opioid dependence in adult patients in October 2012 under Section 505(b)(2) of the Food, Drug and Cosmetic Act and referenced the approved sublingual tablet formulations of buprenorphine.
    Priority designation is given to therapies that offer potential major advances in treatment, including improved safety, or provide a treatment where no adequate therapy exists. Based upon the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of April 30, 2013 for FDA action on the NDA.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
TTNP.OB
0.4630.000(0.00%)Oct 30 2:14 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.